In May 2025, the National Institutes of Health (NIH) announced a new funding opportunity for the Rare Diseases Clinical Research Consortia (RDCRC), emphasizing collaborative, multi-site, and patient-centric non-interventional research. Read the news link below
This initiative is a major step forward in rare disease research, focusing on:
Collaboration across institutions and disciplines
Multi-site studies to reach more patients
Patient-centric approaches that put individuals and families first
Non-interventional (observational) research for deeper insights
Each consortium is required to conduct at least one longitudinal non-interventional (observational) study, with additional projects such as:
Natural history studies
Biomarker discovery and validation
The goal: Build robust, regulatory-ready evidence bases to accelerate diagnosis, management, and trial readiness for rare diseases—bringing hope and progress to patients.
Clinakos Inc., we support every effort and opportunity to accelerate rare disease innovation through our comprehensive, robust, multi-modal, high-fidelity, patient-centric data curated across multiple sources and sites.
Every rare disease patient deserves a better, faster diagnosis with answers, care, and hope
Reach out to us to learn more at https://lnkd.in/gp3gUmXc
Follow us at Clinakos Inc.
Article Link: https://lnkd.in/gDwWKj88
